<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499235</url>
  </required_header>
  <id_info>
    <org_study_id>AKST4290-221</org_study_id>
    <nct_id>NCT04499235</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkahest, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkahest, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects&#xD;
      with bullous pemphigoid (BP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to assess the therapeutic effect&#xD;
      and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP). Subjects will&#xD;
      receive topical mometasone furoate cream (MFC) therapy concurrently with study agent (placebo&#xD;
      or AKST4290) in an inpatient setting until disease control is reached (duration of inpatient&#xD;
      stay is dependent upon individual disease course, but is estimated between 1-3 weeks).&#xD;
&#xD;
      Subjects will receive rescue therapy at any time if their clinical condition worsens or if&#xD;
      their clinical condition fails to improve by the completion of Week 1 on study treatment, as&#xD;
      assessed by the investigator. Rescue therapy will consist of whole-body clobetasol propionate&#xD;
      cream (CPC) (15-50g) and/or oral prednisone (0.5 mg/kg per day), as determined by the&#xD;
      investigator. Subjects who receive rescue therapy will remain in the study until disease&#xD;
      control, unless they are withdrawn or withdraw from participation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Actual">April 14, 2021</completion_date>
  <primary_completion_date type="Actual">March 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who achieve disease control</measure>
    <time_frame>Baseline to up to 3 weeks (until disease control)</time_frame>
    <description>The proportion of subjects who achieve disease control (≤ 3 new lesions/day and healing of existing lesions) without requiring rescue therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by the incidence, seriousness and severity of AEs</measure>
    <time_frame>Baseline to 5 weeks</time_frame>
    <description>Treatment emergent AEs summarized by MedDRA coding terms; separate tabulations will be produced for incidence, seriousness and severity of AEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease control</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Time to disease control will be compared between treatment groups by treatment day and week using a Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue therapy</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Time to rescue therapy will be compared between treatment groups by treatment day and week using a Kaplan-Meier curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Bullous Pemphigoid Disease Area Index (BPDAI) score</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Change from baseline in BPDAI score by treatment week and at disease control. Scores can range from 0 to 360 for BPDAI total activity and 0 to 12 for BPDAI damage, with higher scores indicating greater disease activity or damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Bullous Pemphigoid Disease Area Index Visual Analog Scale (BPDAI-VAS)</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Change from baseline in pruritus as evaluated by the BPDAI-VAS by treatment week and at disease control. Scores can range from 0 to 30, with higher scores indicating a worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cumulative steroid exposure</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Evaluation of total cumulative steroid exposure at baseline, by treatment week, and at disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum daily steroid dose</measure>
    <time_frame>Baseline to 3 weeks</time_frame>
    <description>Evaluation of maximum daily steroid dose at baseline, by treatment week, and at disease control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pemphigoid, Bullous</condition>
  <arm_group>
    <arm_group_label>Mometasone furoate + AKST4290</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive mometasone furoate concurrently with AKST4290, 400 mg twice daily, until disease control is reached.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mometasone furoate + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive mometasone furoate concurrently with placebo until disease control is reached.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
    <description>Topical mometasone furoate</description>
    <arm_group_label>Mometasone furoate + AKST4290</arm_group_label>
    <arm_group_label>Mometasone furoate + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AKST4290</intervention_name>
    <description>Oral AKST4290</description>
    <arm_group_label>Mometasone furoate + AKST4290</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral placebo</description>
    <arm_group_label>Mometasone furoate + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of mild to moderate BP at screening.&#xD;
&#xD;
          -  Treatment naïve or initiation of whole-body high potency topical steroid treatment ≤ 7&#xD;
             days of screening (lesion-only treatment for any amount of time with any topical&#xD;
             steroids prior to screening is allowed without restriction).&#xD;
&#xD;
          -  Provide a signed and dated informed consent form in accordance with local regulations&#xD;
             and/or IRB/IEC guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe BP.&#xD;
&#xD;
          -  Initiation of gliptins and other treatments (e.g., etanercept, sulfasalazine,&#xD;
             furosemide, penicillin) that can trigger BP if this treatment was started within 4&#xD;
             weeks prior to screening and is considered possibly related to the onset of BP.&#xD;
&#xD;
          -  Any concomitant medications in the last 3 months prior to screening and assessed by&#xD;
             the investigator as possibly related to the development of BP.&#xD;
&#xD;
          -  Planned use of intravenous immunoglobulin or other concomitant treatments for BP&#xD;
             (i.e., doxycycline, dapsone) during the study period.&#xD;
&#xD;
          -  Use of systemic immunosuppressants (i.e., mycophenolate, azathioprine, methotrexate)&#xD;
             within 4 weeks prior to screening.&#xD;
&#xD;
          -  Treatment with rituximab within 1 year prior to screening.&#xD;
&#xD;
          -  Subjects taking warfarin.&#xD;
&#xD;
          -  Use of systemic steroids (&gt;10 mg prednisone or equivalent/day) within 14 days of first&#xD;
             dose of study agent or known diseases (other than BP) that could require the use of&#xD;
             systemic steroids within the study period.&#xD;
&#xD;
          -  Clinically relevant abnormal laboratory value at screening, including hematology,&#xD;
             blood chemistry, or urinalysis (laboratory testing may be repeated once during the&#xD;
             screening phase).&#xD;
&#xD;
          -  Participation in studies of investigational drugs must have been discontinued within&#xD;
             30 days or 5 half lives of the drug (whichever was longer) prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alkahest Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Alkahest, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf Klinik für Dermatologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen - Hautklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Klinik für Dermatologie, Allergologie und Venerologie (Hautklinik) Exzellenzzentrum Entzündungsmedizin</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R. Universitätshautklinik</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz Hautklinik Clinical Research Center (CRC)</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune disease</keyword>
  <keyword>Skin disease</keyword>
  <keyword>Vesiculobullous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

